Marker Therapeut Stock Price, News & Analysis

Marker Therapeutics (Nasdaq: MRKR), a clinical-stage immuno-oncology company, announced that its President and CEO, Dr. Juan Vera, will present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. This event will take place on February 25, 2025.

Dr. Vera is scheduled to present an overview of Marker’s technology and clinical developments on Tuesday, February 25, 2025, at 3:30 PM Eastern Time (ET). Registered participants can access the presentation through the event portal on the day of the event.

Marker Therapeutics (MRKR) has secured a $16.1 million private placement through the sale of 5,031,250 shares of common stock and accompanying warrants. The financing, priced at $3.20 per share, includes participation from Blue Owl Healthcare Opportunities, NEA, and Aisling Capital.

The proceeds will primarily support the clinical advancement of the company's Phase 1 APOLLO study investigating MT-601, a multi-antigen recognizing T cell product, in lymphoma patients who have relapsed after anti-CD19 CAR-T cell therapy or where such therapy isn't an option.

The warrants will be exercisable upon shareholder approval with a five-year term and an exercise price of $4.03 per share. Canaccord Genuity leads the placement with Brookline Capital Markets as co-placement agent.

Marker Therapeutics (MRKR) reported positive clinical updates from its Phase 1 APOLLO study of MT-601 in lymphoma patients. The study showed 78% objective response rates with 44.4% complete response in patients who relapsed after anti-CD19 CAR-T therapy or where CAR-T wasn't an option. Out of 10 treated patients, data is available for 9 participants from 5 U.S. clinical sites.

MT-601 demonstrated strong safety profile with no immune-effector cell associated neurotoxicity syndrome (ICANS) and only one Grade 1 cytokine release syndrome case. Long-term follow-up data of 6-12 months is available for three patients, with ongoing monitoring for response durability. The treatment showed efficacy in heavily pre-treated patients who had received 3-12 prior lines of therapy.

Marker Therapeutics (MRKR) has been awarded a $9.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to support clinical investigation of MT-601 in metastatic pancreatic cancer patients. The grant will fund the Phase 1 PANACEA study evaluating safety and tolerability of their multi-tumor associated antigen T cell product.

MT-601 is currently being studied in CD19-CAR relapsed lymphoma patients, with preliminary data showing sustained objective responses in three participants. The therapy targets six tumor-specific antigens and shows promise beyond lymphoma. Previous studies at Baylor College of Medicine using similar technology showed favorable results in pancreatic cancer patients, with 1 complete response, 3 partial responses, and 6 stable disease cases out of 13 patients.

Including this grant, MRKR has secured over $30 million in non-dilutive funding, including an additional $2 million NIH SBIR grant for pancreatic cancer research. The company plans to initiate the pancreatic cancer clinical program in 2025.

Marker Therapeutics (MRKR), a clinical-stage immuno-oncology company, announced its participation in the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators & Investors Symposium. Juan Vera, M.D., President and CEO, will present on December 12, 2024, at 1:30 PM EST.

The presentation will showcase Marker's technology and clinical developments in T cell-based immunotherapies for treating hematological malignancies and solid tumor indications. Registered participants can access the presentation through the event portal, and a replay will be available on the Company's IR website under Events & Presentations.

Marker Therapeutics (Nasdaq: MRKR), a clinical-stage immuno-oncology company, announced its participation in the upcoming Citizens JMP Hematology and Oncology Summit on December 2, 2024. CEO Juan Vera will present the company's technology and clinical developments at 11 AM EST during this virtual event.

The presentation will showcase Marker's focus on developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumor treatments. Following the presentation, a replay will be available on the company's IR website. The management team will also conduct one-on-one meetings with registered investors to discuss business and clinical development strategies.

Marker Therapeutics (MRKR) reported Q3 2024 financial results and business updates. The company received two $2 million NIH SBIR grants to support MT-601 clinical trials in lymphoma and pancreatic cancer patients. The ongoing Phase 1 APOLLO study for MT-601 in lymphoma patients shows promising activity, with preliminary data expected by year-end. Financial highlights include $9 million in cash and cash equivalents, expected to fund operations into October 2025. Q3 2024 showed R&D expenses of $3.5 million, G&A expenses of $0.9 million, and a net loss of $2.3 million.

Marker Therapeutics (Nasdaq: MRKR) reported Q2 2024 financial results and provided business updates. Key highlights include:

1. Preliminary safety and efficacy data from the Phase 1 APOLLO study of MT-601 in lymphoma patients showed objective responses in 3 out of 3 participants.

2. MT-601 was well-tolerated with no cytokine release syndrome or neurotoxicity observed.

3. Marker received a $2 million NIH SBIR grant to support MT-601 clinical investigation.

4. Q2 2024 financial results: $7.8 million in cash and cash equivalents, $2.3 million in R&D expenses, $1.1 million in G&A expenses, and a net loss of $2.2 million.

5. The company expects its cash to fund operations into Q4 2025.

Marker Therapeutics (Nasdaq: MRKR) has been awarded a $2 million grant from the NIH Small Business Innovation Research program to support the clinical investigation of MT-601 in patients with non-Hodgkin's lymphoma (NHL) who have relapsed following anti-CD19 CAR T cell therapy. The grant will fund the nationwide multi-center Phase 1 APOLLO study, evaluating the safety and efficacy of MT-601, a multi-tumor associated antigen-specific T cell product.

The company has now received over $19 million in non-dilutive funding. Preliminary results from the APOLLO study show objective responses in all three study participants treated at City of Hope, with no cytokine release syndrome or immune effector cell associated neurotoxicity syndrome observed. This grant supports Marker's efforts to address the unmet medical need for patients who relapse after CD19-targeting CAR-T cell therapy.